Key result
Higher CHADS2 score linked to ~31% greater major event risk per point in CAD without AF.
Why the study?
The CHADS 2 score has been mainly used to predict cerebrovascular accidents in atrial fibrillation patients, but its value for risk stratification in coronary artery disease patients without atrial fibrillation is uncertain.
Does the CHADS2 score predict adverse cardiovascular and cerebrovascular events in patients with coronary artery disease requiring PCI but without atrial fibrillation?
Cohort (n=7,082)
Yes
Does the CHADS2 score predict adverse cardiovascular and cerebrovascular events in patients with coronary artery disease requiring PCI but without atrial fibrillation?
Hazard Ratio: 1.31 (95% CI 1.17–1.47)
p-value: p=<0.001
The CHADS2 score, traditionally used for atrial fibrillation, is an independent predictor of adverse cardiovascular and cerebrovascular events in patients with coronary artery disease undergoing PCI without atrial fibrillation.
May support CHADS2 for risk stratification in CAD patients post-PCI without AF; hypothesis-generating and requires prospective validation.
Background The CHADS 2 score has mainly been used to predict the likelihood of cerebrovascular accidents in patients with atrial fibrillation. However, increasing attention is being paid to this scoring system for risk stratification of patients with coronary artery disease. We investigated the value of the CHADS 2 score in predicting cardiovascular/cerebrovascular events in coronary artery disease patients without atrial fibrillation. Methods and Results This was a multicenter, observational cohort study. The subjects had been admitted to one of the participating institutions with coronary artery disease requiring percutaneous coronary intervention. We calculated the CHADS 2 scores for 7082 patients (mean age, 69.7 years; males, 71.9%) without clinical evidence of atrial fibrillation. Subjects were subdivided into low‐ (0–1), intermediate‐ (2–3), and high‐score (4–6) groups and followed for 1 year. The end point was a composite of cardiovascular/cerebrovascular death, nonfatal myocardial infarction, and ischemic stroke at 1‐year follow‐up. Rates of triple‐vessel/left main trunk disease correlated positively with CHADS 2 score categories. CHADS 2 scores among single, double, and triple‐vessel/left main trunk groups were 2 (1–2), 2 (1–3), and 2 (2–3), respectively ( P <0.001). A total of 194 patients (2.8%) had a cardiovascular/cerebrovascular event, and Kaplan–Meier analysis demonstrated a significantly higher probability of cardiovascular/cerebrovascular events in proportion to a higher CHADS 2 score (log‐rank test, P <0.001). Multivariate Cox hazard analysis identified CHADS 2 score (per 1 point) as an independent predictor of cardiovascular/cerebrovascular events (hazard ratio, 1.31; 95% CI , 1.17–1.47; P <0.001). Conclusions This large cohort study indicated that the CHADS 2 score is useful for the prediction of cardiovascular/cerebrovascular events in coronary artery disease patients without atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Tabata et al. (2017) conducted a cohort in Coronary artery disease requiring percutaneous coronary intervention without atrial fibrillation (n=7,082). CHADS 2 score vs. Lower CHADS 2 score was evaluated on Composite of cardiovascular/cerebrovascular death, nonfatal myocardial infarction, and ischemic stroke at 1-year follow-up (HR 1.31, 95% CI 1.17-1.47, p=<0.001). Higher CHADS 2 score was an independent predictor of cardiovascular/cerebrovascular events in CAD patients without atrial fibrillation (HR 1.31 per 1 point; 95% CI 1.17-1.47; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: